EMAS Position Statements and Clincial Guides

Subscribe to collection
FilterHide Filter
  • Review article

    Osteoporosis management in patients with breast cancer: EMAS position statement

    Maturitas
    Vol. 95p65–71Published online: October 6, 2016
    • Florence A. Trémollieres
    • Iuliana Ceausu
    • Herman Depypere
    • Irene Lambrinoudaki
    • Alfred Mueck
    • Faustino R. Pérez-López
    • and others
    Cited in Scopus: 33
      Breast cancer remains the most frequent cancer in women and its incidence is increasing. However, the mortality rate has stabilized due to the progress made in the treatment of breast cancer over the last decade. In premenopausal women with hormone receptor-positive breast cancer, the goal of adjuvant treatment is to inhibit the impact of estrogen on the breast, either by blocking the estrogen receptors (with the use of tamoxifen) or by suppressing ovarian function (through surgical oophorectomy or treatment with luteinizing hormone-releasing hormone (LHRH) agonist).

    The content on this site is intended for healthcare professionals.


    We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the Cookie Preference Center for this site.
    Copyright © 2023 Elsevier Inc. except certain content provided by third parties.


    RELX